Liquidia (NASDAQ:LQDA) Insider Sells $1,748,566.40 in Stock

Liquidia Corporation (NASDAQ:LQDA) insider Sarah Krepp sold 24,880 shares of the firm’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $70.28, for a total transaction of $1,748,566.40. Following the transaction, the insider directly owned 121,863 shares of the company’s stock, valued at approximately $8,564,531.64. This trade represents a 16.95% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sarah Krepp also recently made the following trade(s):

• On Monday, June 1st, Sarah Krepp sold 276 shares of Liquidia stock. The stock was sold at an average price of $60.87, for a total transaction of $16,800.12.
• On Monday, April 13th, Sarah Krepp sold 4,557 shares of Liquidia stock. The stock was sold at an average price of $38.37, for a total transaction of $174,852.09.

Liquidia Trading Up 0.9%

Shares of Liquidia stock opened at $68.65 on Thursday. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 2.03. The firm has a fifty day moving average price of $51.76 and a 200 day moving average price of $41.76. Liquidia Corporation has a 1 year low of $11.85 and a 1 year high of $73.22. The stock has a market cap of $6.11 billion, a PE ratio of 490.39 and a beta of 0.58.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings results on Monday, May 11th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.41 by $0.11. The company had revenue of $132.87 million for the quarter, compared to analyst estimates of $119.44 million. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The company’s quarterly revenue was up 4187.1% on a year-over-year basis. Equities research analysts predict that Liquidia Corporation will post 2.97 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts recently commented on LQDA shares. Needham & Company LLC raised their price target on shares of Liquidia from $54.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, May 11th. Zacks Research upgraded shares of Liquidia from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Liquidia in a research report on Tuesday, April 21st. Raymond James Financial restated a “strong-buy” rating and set a $68.00 price target on shares of Liquidia in a research report on Thursday, June 4th. Finally, Wall Street Zen upgraded shares of Liquidia from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 16th. Three investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $60.29.

Hedge Funds Weigh In On Liquidia

Several hedge funds and other institutional investors have recently modified their holdings of LQDA. Farallon Capital Management LLC lifted its stake in shares of Liquidia by 102.1% in the third quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock worth $194,783,000 after buying an additional 4,326,876 shares in the last quarter. TCG Crossover Management LLC purchased a new position in shares of Liquidia in the third quarter worth about $38,887,000. MPM Bioimpact LLC lifted its stake in shares of Liquidia by 600.4% in the fourth quarter. MPM Bioimpact LLC now owns 1,400,869 shares of the company’s stock worth $48,316,000 after buying an additional 1,200,869 shares in the last quarter. Voloridge Investment Management LLC purchased a new position in shares of Liquidia in the third quarter worth about $12,571,000. Finally, Apis Capital Advisors LLC purchased a new position in shares of Liquidia in the third quarter worth about $9,569,000. 64.54% of the stock is owned by hedge funds and other institutional investors.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).